ATE378407T1 - Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen - Google Patents
Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungenInfo
- Publication number
- ATE378407T1 ATE378407T1 AT95918920T AT95918920T ATE378407T1 AT E378407 T1 ATE378407 T1 AT E378407T1 AT 95918920 T AT95918920 T AT 95918920T AT 95918920 T AT95918920 T AT 95918920T AT E378407 T1 ATE378407 T1 AT E378407T1
- Authority
- AT
- Austria
- Prior art keywords
- morphogen
- methods
- cell surface
- surface receptors
- identifying
- Prior art date
Links
- 108010001857 Cell Surface Receptors Proteins 0.000 title abstract 3
- 102000006240 membrane receptors Human genes 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 4
- 102000005962 receptors Human genes 0.000 abstract 4
- 108020003175 receptors Proteins 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 2
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 abstract 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Peptides Or Proteins (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23642894A | 1994-04-29 | 1994-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE378407T1 true ATE378407T1 (de) | 2007-11-15 |
Family
ID=22889467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95918920T ATE378407T1 (de) | 1994-04-29 | 1995-04-28 | Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US5863738A (de) |
| EP (1) | EP0756628B1 (de) |
| JP (1) | JPH10511840A (de) |
| AT (1) | ATE378407T1 (de) |
| AU (1) | AU702163B2 (de) |
| CA (1) | CA2187902A1 (de) |
| DE (1) | DE69535641D1 (de) |
| WO (1) | WO1995030003A2 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994011502A2 (en) * | 1992-11-17 | 1994-05-26 | Ludwig Institute For Cancer Research | Activin receptor-like kinases, proteins having serine threonine kinase domains and their use |
| AU709991B2 (en) * | 1995-08-14 | 1999-09-09 | Creative Biomolecules, Inc. | Binding of osteogenic protein-1 (OP-1) and analogs thereof to the cell surface receptor ALK-1 and analogs thereof |
| US20040002117A1 (en) * | 1998-02-12 | 2004-01-01 | Hogan Patrick G. | Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases |
| PT1131087E (pt) † | 1998-11-13 | 2004-12-31 | Curis Inc | Metodos de alivio de sintomas de cancro |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| JP4813660B2 (ja) * | 1998-11-27 | 2011-11-09 | ダーウィン ディスカバリー リミテッド | 骨鉱化作用を増加するための組成物および方法 |
| DE60033576T2 (de) * | 2000-11-06 | 2007-10-31 | Thrasos, Inc., Waltham | Methoden zum screening knochenmorphogenetishemimetika |
| CA2431035A1 (en) * | 2000-11-06 | 2002-05-10 | Thrasos, Inc. | Computer method and apparatus for classifying objects |
| CA2463143A1 (en) * | 2001-10-31 | 2003-07-10 | Alcon, Inc. | Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma |
| WO2003087763A2 (en) | 2002-04-03 | 2003-10-23 | Celltech R & D, Inc. | Association of polymorphisms in the sost gene region with bone mineral density |
| US7381409B2 (en) | 2003-06-16 | 2008-06-03 | Celltech R&D, Inc. | Antibodies specific for sclerostin and methods of screening and use therefor |
| CA2897218A1 (en) | 2004-06-17 | 2006-01-26 | Thrasos Innovation, Inc. | Tdf-related compounds and analogs thereof |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| NZ565172A (en) * | 2005-07-19 | 2012-12-21 | Stemgen S P A | Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS |
| PT2497780E (pt) | 2005-09-20 | 2015-08-20 | Thrasos Innovation Inc | Compostos relacionados com tdf e seus análogos |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| EP2781222B1 (de) * | 2005-11-23 | 2017-08-02 | Acceleron Pharma, Inc. | Activin-actriia antagonisten zur verwendung in der förderung von knochenwachstum |
| US8859752B2 (en) | 2006-04-18 | 2014-10-14 | The Trustees Of The University Of Pennsylvania | SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP) |
| US8895711B2 (en) * | 2006-04-18 | 2014-11-25 | The Trustees Of The University Of Pennsylvania | Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP) |
| US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| US7947646B2 (en) | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| EP2574671B1 (de) * | 2007-03-19 | 2016-02-03 | National Research Council Of Canada | Antagonisten von Liganden und ihre Verwendung |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| NZ627111A (en) | 2008-11-26 | 2015-10-30 | Amgen Inc | Variants of activin iib receptor polypeptides and uses thereof |
| EP3058986B1 (de) | 2009-03-30 | 2018-05-09 | Acceleron Pharma Inc. | Bmp-alk3-antagonisten und ihre verwendung zur förderung des knochenwachstums |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| EP2681242B1 (de) | 2011-03-01 | 2018-01-24 | Amgen Inc. | Sclerostin- und dkk-1-bispezifische bindemittel |
| EP2688910B1 (de) | 2011-03-25 | 2019-05-29 | Amgen Inc. | Anti-sclerostin-antikörperkristalle und formulierungen davon |
| SI2739311T1 (en) | 2011-08-04 | 2018-07-31 | Amgen Inc. | Method for the treatment of bone defect defects |
| BR112014015003A2 (pt) | 2011-12-19 | 2019-09-24 | Amgen Inc | composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral |
| EP2797953B1 (de) | 2011-12-28 | 2020-06-03 | Amgen Inc. | Verfahren zur behandlung von alveolarknochenverlust durch verwendung von anti-sclerostin-antikörpern |
| US9925260B2 (en) | 2012-07-05 | 2018-03-27 | Ucb Pharma S.A. | Treatment for bone diseases |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| SG11201505960VA (en) | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
| FR3024462A1 (fr) * | 2014-07-29 | 2016-02-05 | Univ Pierre Et Marie Curie Paris 6 | Procede de production in vitro de progeniteurs adipocytaires et d'adipocytes |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| HRP20260414T1 (hr) | 2018-03-30 | 2026-05-08 | Amgen Inc. | C-terminalne varijante protutijela |
| WO2020086580A1 (en) | 2018-10-22 | 2020-04-30 | Carlson William D | Therapeutic combinations of tdfrps and additional agents and methods of use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8827367D0 (en) | 1988-11-23 | 1988-12-29 | Lawrence C A | Spinning of yarn |
| ES2113857T3 (es) * | 1989-03-28 | 1998-05-16 | Genetics Inst | Composiciones osteoinductoras. |
| ES2118723T3 (es) * | 1989-10-17 | 1998-10-01 | Stryker Corp | Dispositivos osteogenicos. |
| ATE197611T1 (de) * | 1991-08-30 | 2000-12-15 | Creative Biomolecules Inc | Screeningverfahren von morphogenischen proteinen |
| AU3920693A (en) * | 1992-03-18 | 1993-10-21 | General Hospital Corporation, The | Four novel receptors of the TGF-beta receptor family |
| DE4225427A1 (de) * | 1992-07-31 | 1994-02-03 | Boehringer Mannheim Gmbh | Verfahren zur Gewinnung rekombinanter, biologisch aktiver, eukaryontischer alkalischer Phosphatase |
| WO1994011502A2 (en) * | 1992-11-17 | 1994-05-26 | Ludwig Institute For Cancer Research | Activin receptor-like kinases, proteins having serine threonine kinase domains and their use |
| US6291206B1 (en) * | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| US6248554B1 (en) * | 1993-11-24 | 2001-06-19 | The Procter & Gamble Company | DNA sequence coding for a BMP receptor |
-
1995
- 1995-04-28 AT AT95918920T patent/ATE378407T1/de not_active IP Right Cessation
- 1995-04-28 EP EP95918920A patent/EP0756628B1/de not_active Expired - Lifetime
- 1995-04-28 AU AU24662/95A patent/AU702163B2/en not_active Expired
- 1995-04-28 CA CA002187902A patent/CA2187902A1/en not_active Abandoned
- 1995-04-28 DE DE69535641T patent/DE69535641D1/de not_active Expired - Lifetime
- 1995-04-28 US US08/481,337 patent/US5863738A/en not_active Expired - Lifetime
- 1995-04-28 WO PCT/US1995/005467 patent/WO1995030003A2/en not_active Ceased
- 1995-04-28 JP JP7528497A patent/JPH10511840A/ja not_active Withdrawn
- 1995-06-02 US US08/448,371 patent/US6632618B1/en not_active Expired - Lifetime
-
2001
- 2001-10-18 US US09/982,543 patent/US7067260B2/en not_active Expired - Fee Related
-
2005
- 2005-04-04 US US11/098,889 patent/US20050233379A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10511840A (ja) | 1998-11-17 |
| US7067260B2 (en) | 2006-06-27 |
| WO1995030003A3 (en) | 1995-12-14 |
| AU702163B2 (en) | 1999-02-18 |
| EP0756628B1 (de) | 2007-11-14 |
| US6632618B1 (en) | 2003-10-14 |
| WO1995030003A2 (en) | 1995-11-09 |
| DE69535641D1 (de) | 2007-12-27 |
| US5863738A (en) | 1999-01-26 |
| US20050233379A1 (en) | 2005-10-20 |
| AU2466295A (en) | 1995-11-29 |
| US20020155500A1 (en) | 2002-10-24 |
| CA2187902A1 (en) | 1995-11-09 |
| EP0756628A1 (de) | 1997-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69535641D1 (de) | Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen | |
| NZ500253A (en) | Osteoprotegerin binding proteins and receptors | |
| EP2311955A3 (de) | Osteoprotegerin bindende Proteine und deren Rezeptoren | |
| NZ502391A (en) | Mammalian cytokine: interleukin-B30 and related reagents | |
| DK1005540T3 (da) | IKK-beta-proteiner, nukleinsyrer og fremgangsmåder | |
| NO995458D0 (no) | Humane 12-lignende reseptorproteiner, beslektede reagenser og metoder | |
| ATE370233T1 (de) | Zwei menschliche g-protein-gekoppelte rezeptorproteine: ebv-induzierter gpcr2 (ebi-2) und egd-1-ähnlicher gpcr | |
| DK1012274T3 (da) | Dödsdomæneholdig receptor-4 (DR4: dödsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L) | |
| DK1482042T3 (da) | Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren | |
| WO1997007135A3 (en) | Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof | |
| BR9912455A (pt) | ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória | |
| DK0973794T3 (da) | Netrinreceptorer | |
| DE69735716D1 (de) | Kappa/mu ähnliche proteintyrosinphosphatase, proteintyrosinphosphatase lambda | |
| EP1005539A4 (de) | Ikk-alpha proteine, nukleinsäuren und verfahren | |
| ATE196775T1 (de) | Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon | |
| EP1655382A3 (de) | Dickdarm spezifisches Gen und Protein | |
| EP1065214A4 (de) | Neue, physiologisch aktive peptide und ihre verwendung. | |
| DE69607034D1 (de) | Pcna bindende substanz | |
| SE9602822D0 (sv) | New receptor | |
| EP0846763A3 (de) | R5, ein Protein Phosphatase-1 bindendes Protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |